Triplex formation by the human Ha-ras promoter inhibits Sp1 binding and in vitro transcription.
Charles A. Mayfield(Baylor College of Medicine), Donald M. Miller(University of Louisville), D. I. Jones(Indian Institute of Technology Madras), Mark Squibb(University of Alabama at Birmingham), Jennifer M. Gee(Quadram Institute), Brad Rodu(Baylor College of Medicine), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 65
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k